A government-funded initiative has been launched to seamlessly connect hospitals, governments, insurance companies and medical device manufacturers throughout the healthcare process, based on digital therapeutics and big data. Yonsei University Health System.
Yonsei Severance Hospital recently began prescribing the insomnia DTx Somzz through an integrated platform called Connect-DTx.
How to use
Connect-DTx can collect health data from patient users in near real-time once a DTx is prescribed. Physicians can use this data to adjust and customize a patient's treatment. Connect-DTx can also be used by an inpatient to collect data by linking to her EMR at the hospital.
Beyond care teams, the platform also connects with government regulators and insurance companies. For example, the National Health Insurance Corporation and the Ministry of Food and Drug Safety can easily query the progress of his DTx-based treatment and process insurance claims and reviews through Connect-DTx.
Additionally, DTx manufacturers can track which healthcare institutions are using their products without having to contact each individual for confirmation.
Seoul St. Mary's Hospital, Boramae Hospital, Wonju Severance Christian Hospital, Korea University Anam Hospital, and Seoul National University Bundang Hospital are all in the process of onboarding and implementing Connect-DTx. More DTx devices will be introduced soon for other conditions such as dementia, Parkinson's disease, and smoking cessation.
Why is it important?
In 2022, YUHS received 7.8 billion won ($5.8 million) in funding from the South Korean Ministry of Trade, Industry and Energy for the development of Connect-DTx. The purpose is to provide convenient and secure access to patient health information collected in near real time from DTx devices and the hospital's EMR. This allows doctors to leverage data and become better informed before tailoring treatments to patients. It also makes it easier for governments and insurance companies to review and process insurance claims.
bigger trends
somsThe insomnia DTx developed by Aimmed is the first of its kind to be approved in South Korea. It offers cognitive behavioral therapy (CBT), which is said to help patients get more sleep. Just four months after Amed's approval in January 2023, Vert received a second approval for its insomnia treatment DTx. Welt-I.
These market approvals come as the number of Koreans suffering from insomnia has nearly doubled over the past decade. Currently, at least 15% of the population suffers from chronic insomnia. CBT has become the first-line treatment for this condition, and incorporating CBT into her mobile application helps provide a bridge to this treatment, which is said to be more effective than taking regular sleeping pills.
On record
“With the development of the Connect-DTx platform, industry players such as healthcare institutions, government ministries, and medical device companies can now conveniently and securely leverage medical data to provide personalized treatment to patients. ” said Mr. Joon, Director of YUHS Digital Health Department. -Seok Lim says of his Connect-DTx:
„We hope that this will be the catalyst for an era of cutting-edge medical care based on big data that systematically analyzes algorithms and treatment patterns in patients' daily lives, which have been difficult to understand until now,“ he added.